Précisez une action ou une cryptomonnaie dans la barre de recherche pour obtenir un récapitulatif
Solasia Pharma KK
4597Solasia Pharma K.K. engages in the development and marketing of oncology drugs in Japan and other Asian countries. The company offers episil oral liquid for the protection and relief of oral pain associated with oral mucositis/stomatitis caused by chemotherapy and radiotherapy for cancer; Sancuso, a transdermal delivery system that delivers granisetron, an anti-emetic into the patient's bloodstream for the treatment of chemotherapy induced nausea and vomiting; and Darvias injection, and antineoplastic agent/organic arsenic product indicated for relapsed or refractory peripheral T-cell lymphoma. It is also involved in the development of SP-04, a chemotherapy induced peripheral neuropathy which is in pre-clinical stage. The company was founded in 2006 and is based in Tokyo, Japan. Address: Sumitomo Fudosan Shiba-Koen Tower, Tokyo, Japan, 105-0011
Analytics
Objectif de Cours de WallStreet
8 423.87 JPYRatio C/B
–Rendement du dividende
–Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Année actuelle
L'année dernière
Trimestre en cours
Le dernier trimestre
Chiffres clés 4597
Analyse des dividendes 4597
Croissance des dividendes sur 5 ans
–Croissance continue
–Ratio de distribution Moyenne sur 5 ans
–Historique des dividendes 4597
Valorisation des titres 4597
financières 4597
Résultats | 2019 | Dynamique |